![Yan Hai](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Yan Hai has held the title of President & Chief Executive Officer at REMD Biotherapeutics, Inc. since 2011.
Dr. Hai is the founder of REMD Biotherapeutics, Inc., which was founded in 2011.
Yan Hai active positions
Companies | Position | Start |
---|---|---|
REMD Biotherapeutics, Inc.
![]() REMD Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology REMD Biotherapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing protein-based therapies to treat metabolic diseases and other serious illnesses. The private company was founded in 2011 by two former Amgen research scientists, Yan Hai and Tom Boone, and is based in Camarillo, CA, with additional facilities in Beijing. REMD Biotherapeutics has established several unique antibody research and development platforms, including a G protein-coupled receptors (GPCRs) antibody platform, a Synermab bispecific antibody platform, and a tumor-activating interferon (TAI) bifunctional antibody interferon fusion platform. The company's most advanced program is volagidemab (REMD-477), a fully human antibody that has completed phase 2 clinical studies in type 1 and type 2 diabetes and is in preparation for initiating multi-center clinical phase 3 studies in type 1 diabetes. | Chief Executive Officer | 01/01/2011 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
REMD Biotherapeutics, Inc.
![]() REMD Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology REMD Biotherapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing protein-based therapies to treat metabolic diseases and other serious illnesses. The private company was founded in 2011 by two former Amgen research scientists, Yan Hai and Tom Boone, and is based in Camarillo, CA, with additional facilities in Beijing. REMD Biotherapeutics has established several unique antibody research and development platforms, including a G protein-coupled receptors (GPCRs) antibody platform, a Synermab bispecific antibody platform, and a tumor-activating interferon (TAI) bifunctional antibody interferon fusion platform. The company's most advanced program is volagidemab (REMD-477), a fully human antibody that has completed phase 2 clinical studies in type 1 and type 2 diabetes and is in preparation for initiating multi-center clinical phase 3 studies in type 1 diabetes. | Health Technology |
- Stock Market
- Insiders
- Yan Hai